key: cord-0805517-1q9xf53b
authors: Sharma, Sapna; Vercruysse, Thomas; Sanchez-Felipe, Lorena; Kerstens, Winnie; Abdelnabi, Rana; Foo, Caroline; Lemmens, Viktor; Van Looveren, Dominique; Maes, Piet; Baele, Guy; Weynand, Birgit; Lemey, Philippe; Neyts, Johan; Thibaut, Hendrik Jan; Dallmeier, Kai
title: Universal COVID-19 vaccine with updated spike antigen confers full protection against all SARS-CoV-2 variants of concern
date: 2021-11-24
journal: bioRxiv
DOI: 10.1101/2021.11.12.468374
sha: 9e0155fb02bedd39680690776025bc65742709b9
doc_id: 805517
cord_uid: 1q9xf53b

All currently used first-generation COVID-19 vaccines are based on prototypic spike sequences from ancestral 2019 SARS-CoV-2 strains. However, it remains unclear to which extent vaccination protects against variants of concern (VOC) which fuel the ongoing pandemic. Here we show in a stringent hamster challenge model that immunization using prototypic spike expressed form a potent YF17D viral vector (Sanchez-Felipe et al. 2021) provides vigorous protection against infection with ancestral virus and VOC Alpha (B.1.1.7), however, is insufficient to provide optimal protection against the Beta (B.1.351) variant. To improve vaccine efficacy, a revised vaccine candidate was created that carries a modified spike antigen designed to cover the entire VOC spectrum. Vaccination of hamsters with this updated vaccine candidate provides full protection against intranasal challenge with all four VOC Alpha, Beta, Gamma (P.1) and Delta (B.1.617.2) resulting in complete elimination of infectious virus from the lungs and a marked improvement in lung pathology. Vaccinated hamsters did also no longer transmit the Delta variant to non-vaccinated sentinels. Overall, our data indicate that current first-generation COVID-19 vaccines need to be urgently updated to cover emerging sequence diversity of VOCs to maintain vaccine efficacy and to impede virus spread at the community level.

To assess VE of prototypic spike antigen against VOCs, hamsters were vaccinated twice with each 10 4 94 PFU of YF-S0 (S0) or sham at day 0 and 7 via the intraperitoneal route (Sanchez-Felipe et al., 2021) 95 ( Fig. 1A) . Serological analysis at day 21 confirmed that 30/32 (94%) vaccinated hamsters had 96 seroconverted to high levels of nAbs against prototypic SARS-CoV-2 with geometric mean titre (GMT) 97 of 2.3 log10 (95% CI 2.0-2.6) (Fig. 1B) . Next, animals were challenged intranasally with 1x10 3 TCID50 98 of either prototypic SARS-CoV-2, VOC Alpha or Beta as established and characterized before in the 99 hamster model (Abdelnabi et al., 2021) . At day four after infection (4 dpi), viral replication was 100 determined in lung tissue by qPCR and virus titration (Fig. 1C, D) . In line with what was originally 101 described for S0 (Sanchez-Felipe et al., 2021), a marked reduction in viral RNA and infectious virus 102 loads down to undetectable levels (up to 6log10 reduction) was observed in the majority of animals 103 challenged with either prototypic SARS-CoV-2 (8/10; 86% VE) or VOC Alpha (9/10; 88% VE). In 104 those animals (2/10 and 1/10, respectively) that were not completely protected, virus loads were at least 105 100 times lower than in infected sham controls. By contrast and despite full immunization, S0 106 vaccination proved to be less effective against VOC Beta, with only 4/12 hamsters without detectable 107 infectious virus (60% VE). Nonetheless, in the remaining 8/12 animals with breakthrough infection by 108 VOC Beta, viral replication was tempered as vaccination still resulted in a 10 to 100-fold reduction in 109 infectious virus titres relative to sham.

Logistic regression used to define immune correlates of protection (van der Lubbe et al., 2021) 111 confirmed that comparable nAb levels were required for protection against prototypic SARS-CoV-2 112 (1.5 log10 for 50% and 2.9 log10 for 90% protection) and VOC Alpha (1.2 log10 for 50% and 2.5 log10 for 113 90% protection) (Fig. 1E) . Intriguingly, for VOC Beta a markedly (up to 25x) higher nAb threshold (2.6 114 log10) was required for 50% protection. Importantly, no 90% protective nAb threshold could be defined 

1B) and protective immunity against prototypic SARS-CoV-2 and VOC Alpha ( Fig. 1C-E) , the 122 prototypic spike antigen failed to induce consistent nAb responses against remaining VOCs ( Fig. 2A) .

Most importantly, YF-S0 vaccination resulted only in poor seroconversion and low nAb titres against 124 VOC Beta (seroconversion rate 15/32; GMT 1.0 log10, 95% CI of 0.6-1.3;) and Gamma (19/32; GMT 1.3 log10, 95% CI 0.9-1.8). Intriguingly, also a pool of human convalescent serum used as benchmark 126 (WHO standard NIBSC 20/130) originating from 2020 prior to the surge of VOC ( Fig. 2A- (Fig. 2C) . YF-S0* proved to be 135 highly immunogenic against prototypic SARS-CoV-2, with nAb levels reaching GMT of 2.2 log10 (95% 136 CI 1.8-2.6) and a seroconversion rate of 21/24 ( Fig. 2D) , comparable to original YF-S0 (GMT 2.3 log10, 137 95% CI 2.0-2.6; 30/32 seroconversion rate) ( Fig. 2A) . Also, for both constructs, seroconversion rates 138 and nAb levels against VOC Delta were similar (YF-S0: 30/32; GMT 2.0 log10, 95% CI 1.7-2.2; YF-139 S0*: 22/24; GMT 2.0 log10, 95% CI 1.6-2.3). Notably, for YF-S0*, nAb levels and seroconversion rates 140 against VOC Beta (GMT 2.9 log10, 95% CI 2.6-3.2; seroconversion rate 23/24) and Gamma (GMT 3.0 141 log10, 95% CI 2.8-3.2; seroconversion rate 24/24) were markedly increased (by 50 to 80-fold for GMT; 142 1.7 to 2-times more frequent seroconversion) ( Fig. 2A, D) .

We further studied the pattern of cross-reactivity of the sera raised by the original (YF-S0) and updated 144 (YF-S0*) vaccine antigen against four different virus variants (prototype; VOCs Beta, Gamma and 145 Delta) using antigenic cartography . VOC Alpha was not considered since it did not 146 differ from the prototype virus, neither regarding VE of S0 nor nAb titre as correlate protection (Fig. 1) .

Specifically, we constructed a two-dimensional projection that geometrically maps median serum 148 neutralization titres (SNT50) between sera and respective antigens as antigenic distances. This revealed 149 a pattern of antigenic diversification between prototype virus on the one hand and VOCs Beta and 150 Gamma on the other hand, with VOC Delta being mapped closer to the prototype virus as compared to 151 Beta and Gamma. This is consistent with recently described patterns of convergent evolution in spike 152 for VOCs Beta and Gamma, and Delta climbing a different fitness peak (Martin et al., 2021) . In line 153 with the visual pattern of clustering, antigenic distances for S0* sera were significantly larger to 154 prototype and VOC Delta as compared to Beta and Gamma (t-test; p<0.001). Intriguingly, this obvious 155 antigenic drift did not reduce the overall higher potency of S0*, which included an equally strong 156 humoral response to prototypic spike and VOC Delta ( Fig. 2A, D) .

S0*-vaccinated animals were subsequently challenged with each 10 3 TCID50 of either of the four VOCs 158 Alpha, Beta, Gamma or Delta, and sacrificed 4 dpi for assessment of viral loads in the lung (Fig. 2F, G) 159 and associated lung pathology (Fig. 2H, I) . In S0*-vaccinated hamsters, viral RNA loads were uniformly reduced compared to matched sham controls by ~3 (VoC Delta) up to ~6 log10 (VoC Gamma) depending 161 on the respective challenge virus under study (Fig. 2F) . Importantly, no infectious virus could be 162 detected anymore (~6log10 reduction) in any of the animals vaccinated with S0*, irrespective of which 163 VOC they had been exposed to (Fig. 2G) , confirming 100% VE conferred by S0* against all four VOCs.

Protection from infection also translated in a markedly reduced pathology (Fig. 2H, I) 

In contrast, lungs of S0*-vaccinated hamsters remained markedly less affected with a clear reduction in 168 overall histological scores, irrespectively of the VOC used (Fig. 2H, I) . In conclusion, second-169 generation YF-S0* expressing an updated S0* antigen induced consistently high levels of broadly 170 neutralizing antibodies (Fig. 2D) which translated into efficient protection from lower respiratory tract 171 infection and COVID-19-like pathology by the entire spectrum of circulating VOCs (Fig. 2G, H) . VE 172 of S0* covered VOC Beta and Gamma, i.e. variants harbouring key mutations K417N/T and E484K 173 escaping original spike-specific nAb activity (Fig. 2B) , and may therefore offer protection against other 174 emerging variants such as VOI Mu (E484K) with a similar signature. 

As expected from previous experiments, viral loads in S0*-vaccinated index animals were much lower 187 than in non-vaccinated index animals, or than in sentinels that had been in close contact with non-188 vaccinated donors (Fig. 3B, C) . Importantly, only very low levels of viral RNA and no infectious virus 189 was observed in non-vaccinated sentinels that had been co-housed with S0*-vaccinated donors. Also, 190 lung pathology was reduced significantly in vaccinated index and co-housed sentinels as compared to 191 sham vaccinated index and respective co-housed sentinels (Fig. 3D) . To our knowledge, this is first 192 experimental evidence for full protection from SARS-CoV-2 transmission by any vaccine. The block 193 conferred by S0* appears to be more complete than that observed in humans by current vaccines (Siddle 194 et al., 2021).

Little is known about how well current first-generation vaccines protect against the full spectrum of Fig. 1F-H) . By contrast, viral replication was reduced to undetectable levels for all four VOCs by 208 YF-S0* vaccination using an updated spike antigen (Fig. 2G) . Finally, S0* blocked transmission of 209 VOC Delta (Fig. 3) . In summary, our findings strongly suggest that first-generation COVID-19 vaccines 

Comparing infectivity and virulence of 367 emerging SARS-CoV-2 variants in Syrian hamsters

STAT2 signaling restricts 370 viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters

SARS-CoV-2 Lineages and Sub-Lineages Circulating 374 Worldwide: A Dynamic Overview

Convergent evolution of SARS-CoV-2 mutations, L452R, E484Q and 377 P681R, in the second wave of COVID-19 in Maharashtra

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-381 elicited antibodies

SARS-CoV-2 variants of concern as of

The impact of SARS-CoV-2 vaccination on Alpha & Delta variant transmission. 385 medRxiv

Changes in symptomatology, reinfection, and 388 transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain 392 that affect recognition by polyclonal human plasma antibodies

SARS-CoV-2 variants B.1.351 and P.1 escape 396 from neutralizing antibodies

The origins of SARS-399

CoV-2: A critical review

Structure-based design of prefusion-stabilized SARS-402 CoV-2 spikes

Stabilizing the closed SARS-CoV-2 spike trimer

Favipiravir at high doses has potent 408 antiviral activity in SARS-CoV-2-infected hamsters

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. 415

Delta spike P681R mutation enhances SARS-CoV-2 fitness over 418 Alpha variant

Effectiveness of Covid-19 Vaccines against 421 the B.1.617.2 (Delta) Variant

Efficacy of the ChAdOx1 nCoV-19 Covid-424 19 Vaccine against the B.1.351 Variant

The emergence and ongoing convergent 427 evolution of the SARS-CoV-2 N501Y lineages

Establishment of the WHO International Standard and Reference Panel for anti-SARS-431 CoV-2antibody

SARS-CoV-2 501Y.V2 434 (B.1.351) elicits cross-reactive neutralizing antibodies. bioRxiv

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus 437 by BNT162b2 vaccine-elicited human sera

COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough

Resurgence of COVID-442 19 in Manaus, Brazil, despite high seroprevalence

Safety and Efficacy of Single-Dose 445

S Vaccine against Covid-19

A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate

Evidence of transmission from fully 452 vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown

Mapping the antigenic and genetic evolution of influenza virus

The global epidemic of SARS-CoV-2 variants and 458 their mutational immune escape

S vaccination protects hamsters against SARS-CoV-2 variants of concern

S protects Syrian hamsters against G614 variant SARS-CoV-2 and does not 466 enhance respiratory disease

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on 471 virus entry, identification of entry inhibitors, and immune responses to vaccines

mRNA-1273 vaccine induces 475 neutralizing antibodies against mutants from global SARS-CoV-2 variants. bioRxiv

Neutralization of variant under investigation 479 B.1.617 with sera of BBV152 vaccinees

Protective efficacy of Ad26.COV2.S 482 against SARS-CoV-2 B.1.351 in macaques

Syrian hamsters were immunized twice 490 intraperitoneally with 10 4 PFU of S0 on day 0 and 7 and inoculated intranasally on day 21 with 491 10 3 median tissue-culture infectious dose (TCID50) of either prototype SARS-CoV-2 (grey 492 circles), VOC Alpha (green triangles) or VOC Beta (blue squares). B, nAb titers against 493 prototypic spike (D614G) pseudotyped virus on day 21 after vaccination. Red datapoint 494 indicates the NIBSC 20/130 human reference sample included as benchmark. C, D, Viral loads 495 in hamster lungs four days after infection quantified by quantitative RT-PCR (C)

Shaded areas indicate 95% CI. LLOQ is lower limit of quantification. Error bars denote 501 median ± IQR. Differences between groups were analyzed using non

Figure 2. A vaccine based on the updated Spike antigen S0* offers complete protection 506 against all four VOCs. A, nAb titers against prototypic (grey), VOC Beta (blue), VOC Gamma 507 (orange) and VOC Delta (purple) spike pseudotyped virus on day 21 after vaccination with 508 prototype YF-S0

B, Neutralization curves for NIBSC 20/130 human reference sample against same set of 510 pseudotyped viruses. C, Schematic of the updated YF-S0* (S0*) vaccine candidate based on 511 VOC Gamma, plus three extra stabilizing proline residues

F, G, Viral loads in 521 hamster lungs four days after infection quantified by quantitative PCR with reverse 522 transcription (RT-qPCR) (F) and virus titration (G). H, cumulative lung pathology scores from 523 H&E-stained slides of lungs for signs of damage. I, Representative H&E-stained images of 524 sham-or S0*-vaccinated hamster lungs after challenge. Perivascular inflammation (black 525 arrows) with focal endothelialitis (green arrows); peri-bronchial inflammation (blue arrows); 526 patches of bronchopneumonia

H&E-stained slides of lungs for signs of damage. Error bars denote median ± IQR. Differences 540 between groups were analyzed using non-parametric Kruskal Wallis test uncorrected for ties. 541 542